TOLREMO therapeutics AG
|Category:||Emerging Biotech Company Presentation|
TOLREMO is a cancer drug resistance company spun out of the ETH Zurich in Switzerland, one of the leading science universities in the world. TOLREMO uses a proprietary drug screening and development platform to develop small molecules that inhibit non-genetic resistance mechanisms (persister cells; adaptive resistance). They can be used in combination with blockbuster cancer drugs such as EGFR or KRAS inhibitors to prevent resistance development. FIH is planned for H1 2023.